PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS — PONAZA  

CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE Clinical Trial

Official title: OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS - PONAZA TRIAL

Status Recruiting

Clinical Trial Summary

This project is strategy aiming to improve the survival of patients with chronic myelogenous leukemia in advanced phase and myeloid blast crisis.

The basis of this strategy is to add the demethylating agent 5-Azacitidine to the tyrosine kinase inhibitor ponatinib and evaluate its activity in 2 cohorts of patients with either chronic myelogenous leukemia in advanced phase or myeloid blast crisis.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Blast Crisis
• CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE
• CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid

• NCT number: NCT03895671
• Study type: Interventional
• Source: Versailles Hospital
• Contact: Mélody FORT
• Phone: +33139239776
• Email: mfort@ch-versailles.fr
• Status: Recruiting
• Phase: Phase 2
• Start date: June 19, 2019
• Completion date: December 1, 2024